Managed Care

Must biosimilar names be distinct? No, experts argue

Must biosimilar names be distinct? No, experts argue

Innovator companies want the FDA to adopt separate names for biosimilars. Manufacturing changes aren't drastic enough to make it necessary, experts argued at an FTC workshop.

CMS projects healthcare spending to rise

CMS projects healthcare spending to rise

By

Researchers says growth will average 5.8% a year between 2012 and 2022. They also anticipate generics will hit a leveling-off point that will drive average Rx prices upwards

Doctors could use more info on health exchanges: study

By

A new survey of doctors reveals how much they know (or don't) about the looming launch of healthcare exchanges.

IMS pitches expanded real-world evidence platform to pharma

By

IMS has added claims data to its real-world evidence (RWE) platform, but can it satisfy industry's demand for RWE as well as a payer can?

McCann Health buys global market research consultancy

By

Double Helix, a healthcare consultancy that operates across three continents, was bought by Interpublic Group's McCann Health, the network said Monday.

Millennium CEO says industry must brace for change

Millennium CEO says industry must brace for change

By

The drug industry is struggling with more than expiring patents and shrinking sales forces, Millennium Pharmaceuticals CEO Deborah Dunsire told industry watchers Tuesday. Rather, it's wrestling with a top-to-bottom revolution.

GfK snags Bridgehead in bid to deepen payer expertise

By

Responding to what it calls an "acute need" among clients for market access counsel, GfK is buying Bridgehead International, a consultancy with offices here and abroad.

Company news: AstraZeneca and Merck

AstraZeneca launched a home-delivery program for breast cancer drug Arimidex through PBM Express Scripts.

Senators slam Pfizer-PBM deal to blunt generic Lipitor

Senators slam Pfizer-PBM deal to blunt generic Lipitor

By

Pfizer's Lipitor had not yet gone off patent before a trio of Senate healthcare heavyweights was firing off letters to the drugmaker assailing its efforts to conserve Lipitor share through a deal with pharmaceutical benefit managers.

Pfizer's post-expiry plan for Lipitor: maximize brand's sales

By

Pfizer said it plans not only to keep Lipitor consumer promotions running past the brand's expiry later this month. It also aims to put an OTC version of the megablockbuster on the market at some point.

Despite HPV vax ad bonanza, low awareness and slacker docs dog uptake

By

A little over half of US girls ages 13 to 17 have not gotten even one dose of the HPV vaccine, and among the main reasons are poor awareness and the failure of doctors to recommend vaccination, a study shows.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.